Brokerages Set Astrana Health, Inc. (NASDAQ:ASTH) PT at $53.29

Shares of Astrana Health, Inc. (NASDAQ:ASTHGet Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $53.2857.

Separately, Zacks Research downgraded shares of Astrana Health from a “strong-buy” rating to a “strong sell” rating in a research report on Monday, September 1st.

Get Our Latest Research Report on Astrana Health

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new position in Astrana Health during the 4th quarter worth $466,000. Dimensional Fund Advisors LP grew its position in Astrana Health by 10.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company’s stock worth $32,968,000 after purchasing an additional 101,192 shares during the last quarter. Hussman Strategic Advisors Inc. grew its position in Astrana Health by 33.3% during the 1st quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the company’s stock worth $2,605,000 after purchasing an additional 21,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Astrana Health by 6.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 499,529 shares of the company’s stock worth $15,490,000 after purchasing an additional 28,200 shares during the last quarter. Finally, Northern Trust Corp grew its position in Astrana Health by 10.1% during the 4th quarter. Northern Trust Corp now owns 467,179 shares of the company’s stock worth $14,730,000 after purchasing an additional 43,032 shares during the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Trading Down 3.6%

NASDAQ ASTH opened at $29.70 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.59 and a quick ratio of 1.59. The firm’s fifty day moving average price is $26.48 and its 200 day moving average price is $28.21. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of 58.24, a price-to-earnings-growth ratio of 0.77 and a beta of 0.85. Astrana Health has a 12 month low of $21.20 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTHGet Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.17). The company had revenue of $654.81 million during the quarter, compared to analysts’ expectations of $639.13 million. Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. The company’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period last year, the business earned $0.40 earnings per share. Astrana Health has set its Q3 2025 guidance at EPS. On average, sell-side analysts expect that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Astrana Health Company Profile

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

Further Reading

Analyst Recommendations for Astrana Health (NASDAQ:ASTH)

Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.